Health
CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients – News-Medical.Net
CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug…
CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodeling seen in chronic interstitial lung disease,…
-
Business23 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business22 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News19 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business19 hours ago1 ASX dividend stock down 43% I’d buy right now